EF Hutton initiated coverage of Carisma Therapeutics (CARM) with a Buy rating and $24 price target Carisma may be the company that creates the first solid tumor CAR therapy using macrophages, the analyst tells investors in a research note. The firm says the company is also working with Moderna to develop an in-vivo CAR-M therapeutic. Success can potentially transform the CAR landscape as we know it today, contends EF.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio